[HTML][HTML] Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD
M Molimard, J Bourcereau, V Le Gros, I Bourdeix - Respiratory medicine, 2005 - Elsevier
Rationale: The Global Initiative for Chronic Obstructive Lung Disease guidelines
recommend bronchodilator reversibility testing to guide treatment decisions. This study …
recommend bronchodilator reversibility testing to guide treatment decisions. This study …
FEV1 reversibility does not adequately predict effect of formoterol via Aerolizer® in chronic obstructive pulmonary disease
JF Muir, D Benhamou, A Cuvelier… - … journal of clinical …, 2004 - Wiley Online Library
Evaluation of patients with chronic obstructive pulmonary disease (COPD) often includes the
use of post‐bronchodilator reversibility testing to guide treatment decisions …
use of post‐bronchodilator reversibility testing to guide treatment decisions …
Bronchodilator reversibility testing in chronic obstructive pulmonary disease
PMA Calverley, PS Burge, S Spencer, JA Anderson… - Thorax, 2003 - thorax.bmj.com
Background: A limited or absent bronchodilator response is used to classify chronic
obstructive pulmonary disease (COPD) and can determine the treatment offered. The …
obstructive pulmonary disease (COPD) and can determine the treatment offered. The …
Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD
M Cazzola, S Centanni, C Regorda, F di Marco… - Pulmonary …, 2001 - Elsevier
We studied 16 patients with stable COPD in a double blind, double dummy, placebo-
controlled, within patient study to see if formoterol could be used as a rescue drug. We …
controlled, within patient study to see if formoterol could be used as a rescue drug. We …
The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD
BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommends the use of forced expiratory volume in 1s (FEV1) to assess airways …
recommends the use of forced expiratory volume in 1s (FEV1) to assess airways …
Faster Onset of Bronchodilation with Formoterol than with Salmeterol in Patients with Stable, Moderate‐Severe Copd: Results of a Randomized, Double‐Blind Clinical …
J Kottakis, GD Cioppa, J Creemers… - Canadian respiratory …, 2002 - Wiley Online Library
OBJECTIVES: To compare the onset and magnitude of bronchodilation after dry powder
inhalations of formoterol fumarate (Foradil Aerolizer) versus salmeterol xinofoate (Serevent …
inhalations of formoterol fumarate (Foradil Aerolizer) versus salmeterol xinofoate (Serevent …
[HTML][HTML] Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD
BR Celli, DP Tashkin, SI Rennard, J McElhattan… - Respiratory …, 2011 - Elsevier
BACKGROUND: Chronic obstructive pulmonary disease (COPD) patients are thought to
have limited bronchodilator response, determined by changes in forced expiratory volume in …
have limited bronchodilator response, determined by changes in forced expiratory volume in …
Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study
C Cote, JL Pearle, A Sharafkhaneh… - Pulmonary pharmacology …, 2009 - Elsevier
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a growing public health
problem that has increased in recent years. It similarly affects men and women, especially …
problem that has increased in recent years. It similarly affects men and women, especially …
Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study
A Johannessen, ER Omenaas, PS Bakke, A Gulsvik - Thorax, 2005 - thorax.bmj.com
Background: The Global Initiative for Obstructive Lung Disease (GOLD) has defined chronic
obstructive pulmonary disease (COPD) as a post-bronchodilator ratio of forced expiratory …
obstructive pulmonary disease (COPD) as a post-bronchodilator ratio of forced expiratory …
Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD
GE La Piana, L Corda, E Bertella… - … Journal of Chronic …, 2011 - Taylor & Francis
Background Use of short-acting β2-agonists in chronic obstructive pulmonary disease
(COPD) during treatment with long-acting β2-agonists is recommended as needed, but its …
(COPD) during treatment with long-acting β2-agonists is recommended as needed, but its …
相关搜索
- reversibility testing clinical efficacy
- reversibility testing formoterol in copd
- bronchodilator reversibility testing
- reversibility testing risk factors
- fev1 reversibility effect of formoterol
- forgotten message bronchodilator reversibility
- outcome measure bronchodilator reversibility
- treatment with formoterol dose response
- formoterol in copd clinical efficacy
- formoterol in copd dose response
- bronchodilator reversibility in copd